Practices

Mergers and Acquisitions

Why Cooley

  • 180+ member team in 19 major business and technology centers in the US, Europe and Asia

  • Broad industry platform with clients across many industries and sophisticated capabilities in all practice areas

  • Excel in deals in the tech, life sciences, artificial intelligence, medical device and healthcare, consumer, education, defense and media industries

  • Given our market position in the medtech and life sciences sectors, we have handled a large number of life sciences M&A transactions, both public and private, and understand unique structuring issues for life sciences companies, including milestone structures, contingent value rights and option structures

  • Primary corporate counsel to 250+ public companies, giving us an unmatched perspective on market deal points and ability to facilitate introductions between buyers and sellers

  • Represent all categories of participants in transactions, including buyers, sellers, major stockholders, venture capitalists, lenders, financial advisors, management, special board committees, individual investors, private equity funds, hedge funds and others

  • Adept at handling all manner of transactions, including domestic and cross-border mergers and acquisitions; strategic deals, including joint ventures, acquisitions of IP assets, patent cross-licenses, complex divestitures and spinoffs; takeover defense and shareholder activism counseling; and multibillion-dollar public company mergers

  • Robust SPAC (special purpose acquisition company) experience and thought leaders in the area, with a repository of market insight and guidance for businesses interested in the IPO alternative

  • Market-leading IP, privacy, technology licensing, life sciences collaborations and licensing, regulatory, government contracts, credit finance, private equity, antitrust, employment, compensation and tax practices to support transactions

Read more

Recognition

  • Chambers: Corporate/M&A: The Elite: USA – Nationwide
  • LSEG: #1 for US M&A by Deal Count (H1 2025)
  • LSEG: #2 for Global M&A by Deal Count (H1 2025)
  • LSEG: #1 for US and Global Life Sciences M&A by Deal Count (H1 2025)
  • LSEG: #2 for US and Global Tech M&A by Deal Count (H1 2025)
  • Bloomberg: #3 for US and Global M&A by Deal Count (H1 2025)
  • Bloomberg: #3 for US and Global Mid-Market M&A by Deal Count (H1 2025)
  • Bloomberg: #1 for US and Global Tech M&A by Deal Count (H1 2025)
  • Mergermarket: #4 for US M&A by Deal Count (H1 2025)
  • Mergermarket: #5 for Global M&A by Deal Count (H1 2025)
  • Mergermarket: #1 for US and Global Life Sciences M&A by Deal Count (H1 2025)

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.